Epilepsy Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Epilepsy Overview

Epilepsy is a chronic neurological disorder characterized by the frequent and recurring seizures leading to unusual behavior. It can be considered as spectrum disorder due to varied types of seizures, causes and different degree of severity. Epilepsy is a condition in which the brain’s function is disrupted due to aberrant or excessive electrical discharges from brain cells.

“Epilepsy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Epilepsy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. Epilepsy Key players such as – Elium Therapeutics, CombiGene, NeuroPro Therapeutics, Otsuka Pharmaceutical Co.,Ltd., Lundbeck A/S, Aadi Bioscience, Inc., Neurona Therapeutics, Longboard Pharmaceuticals, Cerebral Therapeutics LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment 
• Epilepsy Emerging therapies such as – Kv7 Program, CG 01, NPT 2042, OPC-214870, Lu AG06466, ABI-009, NRTX-1001, LP352, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.   
• In September 2022, Amzell is planning to initiate a randomized, open-label superiority study designed to evaluate the efficacy, and safety of AMZ002 in the treatment of infantile spasms, a rare type of epilepsy
• In November 2021 , Amzell and Amring Pharmaceuticals Inc. announced that their lead product in the collaboration, AMZ002, has entered Phase III Clinical Trial in the US for treatment of infantile epileptic disease

Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Epilepsy Pipeline Therapeutics Assessment

• Epilepsy Assessment by Product Type
• Epilepsy By Stage and Product Type
• Epilepsy Assessment by Route of Administration
• Epilepsy By Stage and Route of Administration
• Epilepsy Assessment by Molecule Type
• Epilepsy by Stage and Molecule Type

DelveInsight’s Epilepsy Report covers around 70+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Epilepsy Therapeutics Market include:

Key companies developing therapies for Epilepsy treatment are – Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, CombiGene, and others.

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:

• Kv7 Program: Elium Therapeutics
• CG 01: CombiGene
• NPT 2042: NeuroPro Therapeutics
• OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
• Lu AG06466: Lundbeck A/S
• ABI-009: Aadi Bioscience, Inc.
• NRTX-1001: Neurona Therapeutics
• LP352: Longboard Pharmaceuticals
• CT-010: Cerebral Therapeutics LLC
• EQU 001: Equilibre Biopharmaceuticals
• Darigabat: Cerevel Therapeutics
• ENX-101: Engrail Therapeutic
• AMZ002: Amzell
• XEN496: Xenon Pharmaceuticals Inc.

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight

Epilepsy Pipeline Analysis:

The Epilepsy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
• Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies

Epilepsy Pipeline Market Drivers

• Rising awareness and strategic alliance
• Increasing launch of novel drugs
• High burden of epilepsy

Epilepsy Pipeline Market Barriers

• Loss of patent protection for branded drugs
• High cost of Epilepsy treatment

Scope of Epilepsy Pipeline Drug Insight    

• Coverage: Global
• Key Epilepsy Companies: Elium Therapeutics, CombiGene, NeuroPro Therapeutics, Otsuka Pharmaceutical Co.,Ltd., Lundbeck A/S, Aadi Bioscience, Inc., Neurona Therapeutics, Longboard Pharmaceuticals, Cerebral Therapeutics LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others
• Key Epilepsy Therapies: Kv7 Program, CG 01, NPT 2042, OPC-214870, Lu AG06466, ABI-009, NRTX-1001, LP352, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others
• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
• Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers 

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trial

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Epilepsy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting